Systematic review and meta-analysis of intrathecal drug delivery systems for the treatment of chronic refractory non-cancer pain.
Rui V Duarte, Sue Copley, Alan Batterham et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness and safety of intrathecal drug delivery (ITDD) systems in adults with chronic non-cancer pain. The analysis included 39 studies with a total of 2652 participants. The pooled mean reduction in pain intensity at 12 months was 2.64 on a 0-10 scale, indicating significant pain relief.
Key findings
- Pooled mean reduction in pain intensity was 2.64 (95% CI 2.19 to 3.08) at 12 months.
- 75% probability that pain reduction exceeds the minimum clinically important difference of 2 units.
- All studies reported improvements in function and health-related quality of life.
- Risk of bias was moderate to high for most studies, affecting the certainty of evidence.
Why it matters
Understanding the effectiveness of ITDD for chronic non-cancer pain is crucial for clinicians considering treatment options. This evidence may influence commissioning decisions and patient management strategies in regions where ITDD is not routinely offered.
What to keep in mind
The certainty of evidence is low for pain outcomes and very low for other outcomes due to study limitations, including inconsistent reporting of adverse events.